{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:43:09Z","timestamp":1790106189467,"version":"4.0.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hodgkin Lymphoma is a rare lymphatic system malignancy which has a negative impact on the health of children and adolescents. While high-income regions have seen a decline in mortality rates due to early diagnosis and advances in treatment strategies (e.g., chemotherapy, radiotherapy, and targeted therapy), low- and middle-income countries continue to face high mortality rates due to limited medical resources and delayed treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Employing data from the Global Burden of Disease (GBD) 2021 study, this analysis assessed the burden of Hodgkin lymphoma among children and adolescents from 1990 to 2021. Metrics including incidence, mortality, and disability-adjusted life years (DALYs) were evaluated across Socio-demographic Index (SDI) quintiles. Age-Period-Cohort (APC) and Nordpred models were used to analyze long-term trends and project future disease burden. Additionally, joinpoint regression analysis identified significant temporal shifts in trends throughout the study period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The estimated DALY number was 265,016, and the ASDR among children and adolescents was 9.816 per 100,000 person in 2021. There were 8,700 new HL cases and 3,385 deaths, and the ASIR and ASMR were 0.320 and 0.125 per 100,000 population, respectively. The estimated number of prevalent HL cases was 50,128 worldwide with the ASPR of 2.001 per 100,000 population. Globally, the Hodgkin lymphoma burden was consistently higher in male children and adolescents than in females across all metrics. Results reveal a global decline in age-standardized incidence rates of HL among children and adolescents, with significant regional variations. Low- and middle-income regions experienced an increase in HL burden, while high-income regions showed a decline trend. The case number of HL in the children and adolescents increased from 8,283 in 1990 to 8,700 in 2021, while ASIR declined by 9.52%. The APC model projected a continued decline in HL incidence and mortality globally by 2040. However, health inequalities persist, with low-income countries bearing a disproportionately high burden of HL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The burden of HL among children and adolescents is increasing, with a significant difference by sex, age and regions, which highlight the urgent need for equitable diagnostic and therapeutic access in low-resource settings to meet the 2030 SDG targets on child health.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2025.1629229","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:29:03Z","timestamp":1763706543000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Global burden of Hodgkin lymphoma among children and adolescents: a population-based study using GBD 2021"],"prefix":"10.3389","volume":"13","author":[{"given":"Jie","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindou","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maigeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1200\/jco.23.01799","article-title":"Classic Hodgkin lymphoma in adolescents and young adults","volume":"42","author":"Kelly","year":"2024","journal-title":"J Clin Oncol"},{"key":"B2","article-title":"American Cancer society, Inc","year":"2021"},{"key":"B3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/ajh.26744","article-title":"Sex differences in lymphoma incidence and mortality by subtype: a population-based study","volume":"98","author":"Radkiewicz","year":"2023","journal-title":"Am J Hematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e2024078","DOI":"10.4084\/mjhid.2024.078","article-title":"Pediatric Hodgkin lymphoma in low- and middle-income countries (LMICs). A narrative review","volume":"16","author":"Moleti","year":"2024","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s40265-017-0796-z","article-title":"Anti-PD-1 antibodies as a therapeutic strategy in classical Hodgkin lymphoma","volume":"77","author":"Jain","year":"2017","journal-title":"Drugs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ajh.25071","article-title":"Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management","volume":"93","author":"Ansell","year":"2018","journal-title":"Am J Hematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.puhe.2023.11.023","article-title":"The global burden of lymphoma: estimates from the global burden of disease 2019 study","volume":"226","author":"Shen","year":"2024","journal-title":"Public Health"},{"key":"B8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13045-019-0785-7","article-title":"Burden of lymphoma in China, 2006\u20132016: an analysis of the global burden of disease study 2016","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e084943","DOI":"10.1136\/bmjopen-2024-084943","article-title":"Temporal changes in the burden of leukaemia and lymphoma in the Australasia and Oceania regions, 2010\u20132019: an analysis of the global burden of disease study 2019","volume":"14","author":"Ho","year":"2024","journal-title":"BMJ Open"},{"key":"B10","article-title":"Global health data exchange","year":""},{"key":"B11","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/s0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021","volume":"403","author":"Naghavi","year":"2024","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/nep.14402","article-title":"Structures for quality assurance and measurements for kidney replacement therapies: a multinational study from the ISN-GKHA","volume":"29","author":"Ekrikpo","year":"2024","journal-title":"Nephrology (Carlton)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1158\/1055-9965.Epi-11-0421","article-title":"Age-period-cohort models in cancer surveillance research: ready for prime time?","volume":"20","author":"Rosenberg","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1200\/jco.2014.59.4853","article-title":"Pediatric Hodgkin lymphoma","volume":"33","author":"Mauz-K\u00f6rholz","year":"2015","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s40164-025-00684-x","article-title":"Global burden and trends of hematologic malignancies based on global cancer observatory 2022 and global burden of disease 2021","volume":"14","author":"Pan","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e037505","DOI":"10.1136\/bmjopen-2020-037505","article-title":"Global and regional incidence, mortality and disability-adjusted life-years for Epstein\u2013Barr virus-attributable malignancies, 1990\u20132017","volume":"10","author":"Khan","year":"2020","journal-title":"BMJ Open"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17474086.2025.2558710","article-title":"Global, regional, and national burden of Hodgkin lymphoma, 1990\u20132021, and predictions for 2050: an analysis of the global burden of disease study 2021","volume":"2025","author":"Li","year":"","journal-title":"Expert Rev Hematol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1182\/blood-2009-03-209601","article-title":"A protective role for early oral exposures in the etiology of young adult Hodgkin lymphoma","volume":"114","author":"Cozen","year":"2009","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/annonc\/13.s1.23","article-title":"Viruses and Hodgkin\u2019s lymphoma","volume":"13","author":"Jarrett","year":"2002","journal-title":"Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1080\/08880018.2024.2337627","article-title":"Characterizing age-related differences in Hodgkin lymphoma in children, adolescents and young adults","volume":"41","author":"Kendel","year":"2024","journal-title":"Pediatr Hematol Oncol"},{"key":"B21","article-title":"World Population Prospects 2024, Online Edition","year":"2024"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e035635","DOI":"10.1136\/bmjopen-2019-035635","article-title":"Differences in regional distribution and inequality in health-resource allocation at hospital and primary health centre levels: a longitudinal study in Shanghai, China","volume":"10","author":"Dong","year":"2020","journal-title":"BMJ Open"},{"key":"B23","doi-asserted-by":"publisher","first-page":"i24","DOI":"10.1093\/eurpub\/ckaa033","article-title":"Leaving no one behind: health equity as a catalyst for the sustainable development goals","volume":"30","author":"Buzeti","year":"2020","journal-title":"Eur J Public Health"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1629229\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:29:05Z","timestamp":1763706545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1629229\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":23,"alternative-id":["10.3389\/fped.2025.1629229"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1629229","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"article-number":"1629229"}}